Emergent BioSolutions Secures Over $250 Million in U.S. Government Contracts for Medical Countermeasures

GAITHERSBURG, Md., July 02, 2024 -- Emergent BioSolutions Inc. EBS has recently been awarded contract modifications worth in excess of $250 million by the U.S. government. The company is recognized for its dedication to supplying medical countermeasures and the new funding underscores its pivotal role in national defense and public health readiness.

Expanding Commitment to Public Safety

The adjustments to the existing contracts guarantee the continuous supply of four critical medical countermeasures. These contracts not only reflect the government's confidence in Emergent BioSolutions' track record but also their vigilant efforts to fortify storages in the event of biological and chemical threats, disease outbreaks, and other public health emergencies.

Strengthening National Health Security

Emergent's portfolio of medical countermeasures plays an integral role in the strategic programs designed to protect U.S. citizens. With a legacy of partnering with federal entities, the company's expanding deals with the government are pivotal for its steady revenue flow and underscore its importance in the biopharmaceutical industry's supply chain for emergency preparedness.

Emergent, BioSolutions, Contract